Vistagen Therapeutics (VTGN) Return on Sales (2016 - 2025)
Vistagen Therapeutics (VTGN) has disclosed Return on Sales for 14 consecutive years, with 62.37% as the latest value for Q4 2025.
- Quarterly Return on Sales fell 216.0% to 62.37% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 84.87% through Dec 2025, down 1373.0% year-over-year, with the annual reading at 105.8% for FY2025, 7820.0% down from the prior year.
- Return on Sales hit 62.37% in Q4 2025 for Vistagen Therapeutics, up from 75.26% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 909.0% in Q1 2025 to a low of 427.9% in Q1 2022.
- Historically, Return on Sales has averaged 20.77% across 5 years, with a median of 56.14% in 2024.
- Biggest five-year swings in Return on Sales: crashed -41385bps in 2022 and later skyrocketed 96705bps in 2025.
- Year by year, Return on Sales stood at 29.42% in 2021, then plummeted by -84bps to 54.23% in 2022, then soared by 72bps to 15.45% in 2023, then crashed by -290bps to 60.21% in 2024, then fell by -4bps to 62.37% in 2025.
- Business Quant data shows Return on Sales for VTGN at 62.37% in Q4 2025, 75.26% in Q3 2025, and 61.86% in Q2 2025.